drugset
drugset / Trial / NCT02674750

Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations

NCT02674750 ↗

Phase 2 Completed 70 enrolled Curis, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase 2, open-label, multicenter trial designed to evaluate the efficacy and safety of CUDC-907 in subjects 18 years and older with Relapsed/Refractory (RR) MYC-altered Diffuse Large B-Cell Lymphoma (DLBCL).

Timeline

Start
2016-07
Primary completion
2019-05-28
Completion
2019-05-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Fimepinostat Small molecule — —

Indications

diffuse large B-cell lymphoma